# APOE3 astrocytes can rescue lipid abnormalities and dystrophic neurites of APOE4 human neurons

**Authors:** Dilara O Halim, Erika Di Biase, Amélie Rajon, Luc Jordi, Penelope J Hallett, Ole Isacson

PMC · DOI: 10.1093/pnasnexus/pgag053 · 2026-03-03

## TL;DR

APOE3 astrocytes can reverse lipid-related damage in neurons linked to Alzheimer's disease, unlike APOE4 astrocytes.

## Contribution

This study demonstrates that APOE3 astrocytes rescue lipid abnormalities and dystrophic neurites in APOE4 neurons.

## Key findings

- APOE3 astrocytes prevent cholesterol- and lipid-induced neurite damage in APOE4 neurons.
- APOE3 astrocytes produce larger, more lipidated high-density lipoprotein-like particles compared to APOE4 astrocytes.
- APOE3 astrocytes enhance lipid homeostasis and rescue neurite structural abnormalities relevant to Alzheimer's disease.

## Abstract

Lipid abnormalities are emerging as key pathogenic mechanisms in neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Lewy body dementia. Astrocytes in the brain provide apolipoprotein E (APOE) proteins and influence neuronal metabolism and health. Using live-cell imaging and objective neurite imaging techniques, we induced cellular lipid load (cholesterol and triglycerides) by inhibiting the lysosomal cholesterol transport protein NPC1 in human neuron−astrocyte cocultures and examined the effects of CRISPR-edited APOE3 and APOE4 human astrocytes on the rescue of dystrophic neurites, where axons and dendrites of nerve cells become disfigured. APOE3, but not APOE4 or APOE knockout, astrocytes prevented cholesterol- and lipid-induced neurite damage in APOE4 neurons. In the media of APOE3 neuron−astrocyte cocultures, high-density lipoprotein−like particles were larger and presumably more lipidated than those in equivalent APOE4 cocultures. This discovery highlights that living APOE3 astrocytes control key biological mechanisms by physiologically enhancing lipid cellular homeostasis and rescuing lipid-induced neurite structural abnormalities relevant to Alzheimer's disease and neurodegenerative diseases.

## Linked entities

- **Genes:** APOE (apolipoprotein E) [NCBI Gene 348], NPC1 (NPC intracellular cholesterol transporter 1) [NCBI Gene 4864]
- **Proteins:** APOE (apolipoprotein E), NPC1 (NPC intracellular cholesterol transporter 1)
- **Chemicals:** cholesterol (PubChem CID 5997)
- **Diseases:** Alzheimer's disease (MONDO:0004975), Parkinson's disease (MONDO:0005180), Lewy body dementia (MONDO:0007488)

## Full-text entities

- **Genes:** ABCA1 (ATP binding cassette subfamily A member 1) [NCBI Gene 19] {aka ABC-1, ABC1, CERP, HDLCQTL13, HDLDT1, HPALP1}, SNAP25 (synaptosome associated protein 25) [NCBI Gene 6616] {aka CMS18, DEE117, RIC-4, RIC4, SEC9, SNAP}, CETP (cholesteryl ester transfer protein) [NCBI Gene 1071] {aka BPIFF, HDLCQ10}, NPC1 (NPC intracellular cholesterol transporter 1) [NCBI Gene 4864] {aka NPC, POGZ, SLC65A1}, APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, BACE1 (beta-secretase 1) [NCBI Gene 23621] {aka ASP2, BACE, HSPC104}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}, HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase) [NCBI Gene 3156] {aka LDLCQ3, LGMDR28, MYPLG}, SLC17A6 (solute carrier family 17 member 6) [NCBI Gene 57084] {aka DNPI, VGLUT2}, NEUROG2 (neurogenin 2) [NCBI Gene 63973] {aka Atoh4, Math4A, NGN2, bHLHa8, ngn-2}, APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}, GFAP (glial fibrillary acidic protein) [NCBI Gene 2670] {aka ALXDRD}, LDLR (low density lipoprotein receptor) [NCBI Gene 3949] {aka LDLCQ2}, GBA1 (glucosylceramidase beta 1) [NCBI Gene 2629] {aka GBA, GCB, GLUC}, S100B (S100 calcium binding protein B) [NCBI Gene 6285] {aka NEF, S100, S100-B, S100beta}, MRAP (melanocortin 2 receptor accessory protein) [NCBI Gene 56246] {aka B27, C21orf61, FALP, GCCD2, MRAP1}, DLG4 (discs large MAGUK scaffold protein 4) [NCBI Gene 1742] {aka MRD62, PSD95, SAP-90, SAP90}, MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, LPA (lipoprotein(a)) [NCBI Gene 4018] {aka AK38, APOA, LP}, MAP2 (microtubule associated protein 2) [NCBI Gene 4133] {aka MAP-2, MAP2A, MAP2B, MAP2C}, NTF3 (neurotrophin 3) [NCBI Gene 4908] {aka HDNF, NGF-2, NGF2, NT-3, NT3}, GDNF (glial cell derived neurotrophic factor) [NCBI Gene 2668] {aka ATF, ATF1, ATF2, HFB1-GDNF, HSCR3}, SNCA (synuclein alpha) [NCBI Gene 6622] {aka NACP, PARK1, PARK4, PD1}, APOB (apolipoprotein B) [NCBI Gene 338] {aka FCHL2, FLDB, LDLCQ4, apoB-100, apoB-48}, POU5F1 (POU class 5 homeobox 1) [NCBI Gene 5460] {aka OCT3, OCT4, OCT4Borf1, OTF-3, OTF3, OTF4}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CNTF (ciliary neurotrophic factor) [NCBI Gene 1270] {aka HCNTF}
- **Diseases:** AD (MESH:D000544), Lipid abnormalities (MESH:D011017), neuronal dysfunction (MESH:D009461), amyloid (MESH:C000718787), LBD (MESH:D020961), inflammation (MESH:D007249), ALS (MESH:D000690), cerebral angiopathy (MESH:D016657), degeneration (MESH:D009410), axonal swellings (MESH:D004487), dementia (MESH:D003704), dystrophic (MESH:D020388), NPC (MESH:D052556), Neurite abnormalities (MESH:D058225), Parkinson (MESH:D010302), brain disease (MESH:D001927), cognitive decline (MESH:D003072), PD (MESH:D010300), lipid metabolism (MESH:D052439), glucose hypometabolism (MESH:D018149), damage (MESH:D020263), lysosomal storage disorders (MESH:D016464), abnormalities (MESH:D000014), Neurodegenerative diseases (MESH:D019636), mitochondrial dysfunction (MESH:D028361), neurofibrillary tangles (MESH:D055956), tau abnormalities (MESH:C536599), neurite structural abnormalities (MESH:C566527), NP disease (MESH:D004194)
- **Chemicals:** Tween 20 (MESH:D011136), HCl (MESH:D006851), U18666A (MESH:C006261), dextrose (MESH:D005947), Puromycin (MESH:D011691), TBS-T (MESH:C027647), tris-glycine (MESH:C035647), polyacrylamide (MESH:C016679), sterol (MESH:D013261), doxycycline (MESH:D004318), glycosphingolipid (MESH:D006028), in (MESH:D007204), hAs:1 (MESH:C110615), Filipin (MESH:D005372), Y-27632 (MESH:C108830), esters (MESH:D004952), phospholipids (MESH:D010743), cholesteryl esters (MESH:D002788), sphingolipids (MESH:D013107), glutamate (MESH:D018698), sodium dodecyl sulfate (MESH:D012967), NR (MESH:C044808), paraformaldehyde (MESH:C003043), GlutaMAX (MESH:C054122), oxysterols (MESH:D000072376), Lipid (MESH:D008055), Alexa Fluor 647 (MESH:C569686), triglyceride (MESH:D014280), EDTA (MESH:D004492), DMEM/F12 (-), Cholesterol (MESH:D002784), PVDF (MESH:C024865), LDN-193189 (MESH:C554430), SB431542 (MESH:C459179), phalloidin (MESH:D010590), 18F-FDG (MESH:D019788), Triton X-100 (MESH:D017830)
- **Species:** Mycoplasma (genus) [taxon 2093], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** S2 — Drosophila melanogaster (Fruit fly), Spontaneously immortalized cell line (CVCL_Z232), pTet-O — Mus musculus (Mouse), Hybridoma (CVCL_L845), hAs — Cricetulus griseus (Chinese hamster), Undefined cell line type (CVCL_6758)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13003211/full.md

---
Source: https://tomesphere.com/paper/PMC13003211